Dac S.R.L.
Records under this name other than patents Dac S.R.L. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Dac S.R.L.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,592,444 | Spirocyclic derivatives as histone deacetylase inhibitors Formerly held Lapsed on the fee record Ended Nov 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 26, 2025 | From the USPTO record |
| US 8,242,175 | Class of histone deacetylase inhibitors Formerly held Lapsed on the fee record Ended Aug 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 14, 2024 | From the USPTO record |
| US 8,058,273 | Histone deacetylases inhibitors Formerly held Lapsed on the fee record Ended Nov 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2023 | From the USPTO record |
| US 9,115,148 | Spirocyclic derivatives as histone deacetylase inhibitors Formerly held Lapsed on the fee record Ended Aug 25, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 25, 2023 | From the USPTO record |
| US 8,980,877 | Spirocyclic derivatives as histone deacetylase inhibitors Formerly held Lapsed on the fee record Ended Mar 17, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 17, 2023 | From the USPTO record |
| US 7,803,800 | Histone deacetylases inhibitors Formerly held Lapsed on the fee record Ended Sep 28, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 28, 2022 | From the USPTO record |
| US 8,592,430 | Quinazolin-oxime derivatives as Hsp90 inhibitors Lapsed on the fee record Ended Nov 26, 2017 · From the USPTO record | Lapsed on the fee record | Ended Nov 26, 2017 | From the USPTO record |